Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/07/26
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline HighlightsGlobeNewsWire • 05/07/26
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of NephrologyGlobeNewsWire • 05/04/26
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business HighlightsGlobeNewsWire • 04/30/26
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090GlobeNewsWire • 04/13/26
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation SymposiumGlobeNewsWire • 04/07/26
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day TranscriptSeeking Alpha • 04/02/26
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of DirectorsGlobeNewsWire • 04/01/26
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026GlobeNewsWire • 03/19/26
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?Zacks Investment Research • 03/17/26
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/09/26
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare ConferenceGlobeNewsWire • 03/03/26
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline HighlightsGlobeNewsWire • 02/26/26
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business HighlightsGlobeNewsWire • 02/19/26
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 TranscriptSeeking Alpha • 02/13/26
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewsWire • 02/04/26
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)GlobeNewsWire • 01/06/26
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewsWire • 11/24/25
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 11/11/25